Table 1.
Susceptibility results for 1831 isolates of E. coli from urinary tract infections collected in the USA in 2017 (SENTRY Antimicrobial Surveillance Program).
Fig 1.
National and regional prevalence of ESBL phenotypes, levofloxacin- and trimethoprim-sulfamethoxazole-resistant phenotypes among 1831 isolates of E. coli from UTIs in the USA in 2017.
ESBL = extended spectrum β-lactamase, LEVO-R = levofloxacin-resistant, TMP-SMX-R = trimethoprim-sulfamethoxazole-resistant.
Fig 2.
Antibiotic resistance among 287 ESBL phenotypes of UTI isolates of E. coli collected in the USA in 2017.
Fig 3.
Resistance to meropenem, levofloxacin and trimethoprim-sulfamethoxazole among 287 ESBL phenotypes of E. coli from UTIs in the USA in 2017 according to Census region.
Table 2.
Co-resistance among trimethoprim-sulfamethoxazole-resistant and levofloxacin-resistant E. coli from urinary tract infections collected in the USA in 2017.
Table 3.
Activity of antimicrobial agents against confirmed CTX-M-15 β-lactamase-producing isolates of E. coli collected from UTIs in the USA during 2017.